The Journal of Experimental Medicine · 2014 · 69 citations · 34 references
Life SciencesCell BiologyOncologyCell SignalingNeoplasiaSignal TransductionMalignant NeoplasmsMetabolic ReprogrammingMetabolic Reprogramming In CancerOncogenic ProliferationOncogenic Signaling PathwaysTuberous Sclerosis ComplexCyclooxygenase-2 PathwayMammalian Target Of Rapamycin SignalingMtor SignalingNeoplastic DiseaseNeoplastic ProgressionProstaglandin E2 BiosynthesisProstaglandin ProductionTsc2 Mutations
Lymphangioleiomyomatosis (LAM) is a progressive neoplastic disorder that leads to lung destruction and respiratory failure primarily in women. LAM is typically caused by tuberous sclerosis complex 2 (TSC2) mutations resulting in mTORC1 activation in proliferative smooth muscle-like cells in the lung. The female predominance of LAM suggests that estradiol contributes to disease development. Metabolomic profiling identified an estradiol-enhanced prostaglandin biosynthesis signature in Tsc2-deficient (TSC(-)) cells, both in vitro and in vivo. Estradiol increased the expression of cyclooxygenase-2 (COX-2), a rate-limiting enzyme in prostaglandin biosynthesis, which was also increased at baseline in TSC-deficient cells and was not affected by rapamycin treatment. However, both Torin 1 treatment and Rictor knockdown led to reduced COX-2 expression and phospho-Akt-S473. Prostaglandin production was also increased in TSC-deficient cells. In preclinical models, both Celecoxib and aspirin reduced tumor development. LAM patients had significantly higher serum prostaglandin levels than healthy women. 15-epi-lipoxin-A4 was identified in exhaled breath condensate from LAM subjects and was increased by aspirin treatment, indicative of functional COX-2 expression in the LAM airway. In vitro, 15-epi-lipoxin-A4 reduced the proliferation of LAM patient-derived cells in a dose-dependent manner. Targeting COX-2 and prostaglandin pathways may have therapeutic value in LAM and TSC-related diseases, and possibly in other conditions associated with mTOR hyperactivation.
34
Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression
Arun Sreekumar, Laila Poisson, Thekkelnaycke M. Rajendiran et al. · Nature · 2009 · 2.2K citations · Full text
Medicine, Cancer Biology, Oncology +16
Activation of a Metabolic Gene Regulatory Network Downstream of mTOR Complex 1
Katrin Düvel, Jessica L. Yecies, Suchithra Menon et al. · Molecular Cell · 2010 · 2K citations · Full text
Anne M. Evans, Corey D. DeHaven, Tom Barrett et al. · Analytical Chemistry · 2009 · 1.4K citations
Efficacy and Safety of Sirolimus in Lymphangioleiomyomatosis
Francis X. McCormack, Yoshikazu Inoue, Joel Moss et al. · New England Journal of Medicine · 2011 · 1.1K citations · Full text
Sandra L. Dabora, Sergiusz Jóźwiak, David Neal Franz et al. · The American Journal of Human Genetics · 2001 · 1K citations · Full text